Mirna Therapeutics IPO

9/30/2015

IPO

$44,100,000

We currently estimate that we will use the net proceeds from this offering, together with the net proceeds from the concurrent private placement as noted below and our existing cash and cash equivalents, as follows: approximately $52.0-$62.0 million to fund clinical development expenses for our lead program, MRX34, which includes approximately $13.0-$16.0 million to complete the Phase 1 clinical trial, including expansion cohorts on multiple indications and/or changes in protocol, approximately $15.0-$18.0 million to initiate the Phase 2 clinical trial for an indication to be determined, and approximately $24.0-$28.0 million, which will include the net proceeds from the concurrent private placement, to fund preclinical and clinical studies for the use of MRX34 in combination with standard of care drugs, approximately $21.0-$25.0 million to fund preclinical and clinical studies for a second product candidate using another to be determined mimic product, and the remainder for preclinical

Private & Independent

Biopharmaceutical

2150 Woodward St. 100
Austin, TX 78744
USA

Mirna Therapeutics, Inc. (NASDAQ: MIRN) is a biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics and is the first to establish clinical proof-of-concept for a microRNA replacement therapy for cancer.